XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 1, 2017, Xenon Pharmaceuticals Inc. (the Company) held
its 2017 Annual Meeting of Shareholders (the Annual Meeting).At
the Annual Meeting, proxies and in-person shareholders
representing 11,251,477 of the Companys common shares, or
approximately 62.5% of the total shares entitled to vote, were
present and voted on the following three proposals, each of which
is described in more detail in the Companys definitive proxy
statement filed with the United States Securities and Exchange
Commission and with the securities commissions in British
Columbia, Alberta and Ontario on April 27, 2017:
Proposal One Election of Directors.The following nominees were
elected as directors to serve until the 2018 annual meeting of
shareholders or until their respective successors are duly
elected and qualified.
|
For |
Withhold |
Broker Non-Votes |
|||
|
Michael Tarnow |
8,575,997 |
719,892 |
1,955,588 |
||
|
Mohammad Azab |
8,592,949 |
702,940 |
1,955,588 |
||
|
Steven Gannon |
8,577,278 |
718,611 |
1,955,588 |
||
|
Michael Hayden |
7,664,472 |
1,631,417 |
1,955,588 |
||
|
Frank Holler |
7,696,353 |
1,599,536 |
1,955,588 |
||
|
Gary Patou |
8,593,553 |
702,336 |
1,955,588 |
||
|
Simon Pimstone |
8,599,235 |
696,654 |
1,955,588 |
||
|
Richard Scheller |
8,869,381 |
426,508 |
1,955,588 |
||
|
Dawn Svoronos |
8,577,967 |
717,922 |
1,955,588 |
||
Proposal Two Appointment of Independent Registered Public
Accounting Firm.The appointment of KPMG LLP as the Companys
independent registered public accounting firm for the ensuing
year was approved as follows:
|
For |
Withhold |
||
|
10,987,565 |
263,912 |
||
Proposal Three Authorization of the Audit Committee to Set the
Remuneration for the Independent Registered Public Accounting
Firm.The authority of the audit committee of the board of
directors to set the remuneration of the auditors for the ensuing
year was approved as follows:
|
For |
Against |
||
|
10,956,971 |
294,506 |
||
About XENON PHARMACEUTICALS INC. (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801. XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Recent Trading Information
XENON PHARMACEUTICALS INC. (NASDAQ:XENE) closed its last trading session down -0.15 at 3.70 with 37,507 shares trading hands.
